What is the value of oncology medicines?
expert_opinion · Level V
Where this comes from
- Record sourced from PubMed, PMID 21057481.
- Also identified by DOI 10.1038/nbt1110-1160.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Coverage with evidence development (CED), rather than quality-adjusted-life-year (QALY) thresholds, offers the best way forward in balancing evidence-based policy for new oncology products with the needs of developers, payers, physicians and patients.
Medical subject headings
- Antineoplastic Agents